Risperidone-d4

• UNSPSC Description:

  Risperidone-d4 is the deuterium labeled Risperidone. Risperidone is a serotonin 5-HT2 receptor blocker, P-Glycoprotein inhibitor and potent dopamine D2 receptor antagonist, with Kis of 4.8, 5.9 nM for 5-HT2A and dopamine D2 receptor, respectively.

• Target Antigen:

  5-HT Receptor; Dopamine Receptor; P-glycoprotein

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  GPCR/G Protein;Membrane Transporter/Ion Channel;Neuronal Signaling

• Field of Research:

  Neurological Disease

• Purity:

  99.40

• Solubility:

  DMSO : 10 mg/mL (ultrasonic;warming)

• Smiles:

  FC1=CC=C(C(C2CCN(C([2H])([2H])C([2H])([2H])C3=C(C)N=C(CCCC4)N4C3=O)CC2)=NO5)C5=C1

• Molecular Weight:

  414.51

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Nyberg S, et al. 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology (Berl). 1993;110(3):265-72.;Zhu HJ, et al. Risperidone and paliperidone inhibit p-glycoprotein activity in vitro. Neuropsychopharmacology. 2007 Apr;32(4):757-64.;Chen ML, et al. Risperidone modulates the cytokine and chemokine release of dendritic cells and induces TNF-α-directed cell apoptosis in neutrophils. Int Immunopharmacol. 2012 Jan;12(1):197-204.;Bardgett ME, et al. Adult rats treated with risperidone during development are hyperactive. Exp Clin Psychopharmacol. 2013 Jun;21(3):259-67.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1020719-76-9